Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Receivables: 2013-2024

Historic Receivables for Ptc Therapeutics (PTCT) over the last 12 years, with Dec 2024 value amounting to $158.6 million.

  • Ptc Therapeutics' Receivables rose 1.55% to $203.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $768.3 million, marking a year-over-year increase of 2.90%. This contributed to the annual value of $158.6 million for FY2024, which is 1.53% down from last year.
  • As of FY2024, Ptc Therapeutics' Receivables stood at $158.6 million, which was down 1.53% from $161.0 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Receivables registered a high of $161.0 million during FY2023, and its lowest value of $69.9 million during FY2020.
  • Moreover, its 3-year median value for Receivables was $158.6 million (2024), whereas its average is $158.4 million.
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 57.95% in 2021, then decreased by 1.53% in 2024.
  • Ptc Therapeutics' Receivables (Yearly) stood at $69.9 million in 2020, then soared by 57.95% to $110.5 million in 2021, then soared by 40.88% to $155.6 million in 2022, then rose by 3.48% to $161.0 million in 2023, then fell by 1.53% to $158.6 million in 2024.